Key clinical point : Continuation of natalizumab during the first trimester may lower the risk for disease reactivation during pregnancy in patients with active multiple sclerosis (MS).
Major finding : The secured first trimester (SFT) group vs secured conception (SC) group was associated with lower rates of relapse (3.6% vs 38.5%; P = .008) and disability progression (3.6% vs 30.8%; P = .03) during pregnancy.
Study details : Two strategies were compared for women with active MS planning to conceive: stopping natalizumab at the end of the first trimester (SFT, n = 29) and stopping at conception (SC, n = 14).
Disclosures: The study did not receive any funding. Audrey Rico, Adil Maarouf, Clémence Boutiere, Jean Pelletier and Bertrand Audoin reported ties with one or more pharmaceutical companies. Sarah Demortiere reported no disclosures.
Citation: Demortiere S et al. Mult Scler. 2020 Mar 23. doi: 10.1177/1352458520912637 .